{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:58:51Z","timestamp":1791356331927,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40266-013-0065-0","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T08:46:59Z","timestamp":1363164419000},"page":"309-319","source":"Crossref","is-referenced-by-count":34,"title":["Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56\u00a0Years and Older: Results of an Open-Label, Randomized, Controlled Trial"],"prefix":"10.1007","volume":"30","author":[{"given":"Ghassan","family":"Dbaibo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"El-Ayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Hajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narcisa","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"65_CR1","doi-asserted-by":"crossref","unstructured":"Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004;23(12 Suppl):S274\u2013279.","DOI":"10.1097\/01.inf.0000147642.85129.05"},{"issue":"2","key":"65_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","volume":"50","author":"AC Cohn","year":"2010","unstructured":"Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184\u201391.","journal-title":"Clin Infect Dis"},{"key":"65_CR3","unstructured":"Australian Meningococcal Surveillance Programme. Australian Meningococcal Surveillance Programme annual report, 2010. Commun Dis Intell. 2011;35(3):217\u201328."},{"issue":"7","key":"65_CR4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","author":"SJ Gray","year":"2006","unstructured":"Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55(7):887\u201396.","journal-title":"J Med Microbiol"},{"issue":"27 Suppl 2","key":"65_CR5","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","volume":"24","author":"LH Harrison","year":"2009","unstructured":"Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;24(27 Suppl 2):B51\u201363.","journal-title":"Vaccine"},{"issue":"5","key":"65_CR6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/339010","volume":"185","author":"SP Gagneux","year":"2002","unstructured":"Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis. 2002;185(5):618\u201326.","journal-title":"J Infect Dis"},{"issue":"5","key":"65_CR7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","volume":"44","author":"P Boisier","year":"2007","unstructured":"Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657\u201363.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"65_CR8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(02)00455-3","volume":"2","author":"J Decosas","year":"2002","unstructured":"Decosas J, Koama J-BT. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis. 2002;2(12):763\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"65_CR9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3201\/eid1609.100510","volume":"16","author":"JM Collard","year":"2010","unstructured":"Collard JM, Maman Z, Yacouba H, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis. 2010;16(9):1496\u20138.","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"65_CR10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jiph.2010.09.008","volume":"3","author":"ZA Memish","year":"2010","unstructured":"Memish ZA, Goubeaud A, Br\u00f6ker M, et al. Invasive meningococcal disease and travel. J Infect Public Health. 2010;3(4):143\u201351.","journal-title":"J Infect Public Health"},{"issue":"6","key":"65_CR11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1086\/367858","volume":"36","author":"A Wilder-Smith","year":"2003","unstructured":"Wilder-Smith A, Goh KT, Barkham T, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36(6):679\u201383.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"65_CR12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3201\/eid0808.010422","volume":"8","author":"J-F Aguilera","year":"2002","unstructured":"Aguilera J-F, Perrocheau A, Meffre C, et al. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8(8):761\u20137.","journal-title":"Emerg Infect Dis"},{"issue":"21","key":"65_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.17.21.20181-en","volume":"17","author":"I Parent du Chatelet","year":"2012","unstructured":"Parent du Chatelet I, Barboza P, Taha M. W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. Euro Surveill. 2012;17(21):1\u20132.","journal-title":"Euro Surveill"},{"key":"65_CR14","unstructured":"Saudi Ministry of Health Requirements - Hajj. 2012 Jan 9 [online]. Available from URL: http:\/\/www.hajinformation.com\/main\/p3001.htm ."},{"issue":"1","key":"65_CR15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","volume":"19","author":"LH Harrison","year":"2006","unstructured":"Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19(1):142\u201364.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"65_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/erv.11.8","volume":"10","author":"J Poolman","year":"2011","unstructured":"Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10(3):307\u201322.","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"65_CR17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/515346","volume":"178","author":"DM Granoff","year":"1998","unstructured":"Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis. 1998;178(3):870\u20134.","journal-title":"J Infect Dis"},{"issue":"12","key":"65_CR18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","volume":"194","author":"C Auckland","year":"2006","unstructured":"Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745\u201352.","journal-title":"J Infect Dis"},{"issue":"7","key":"65_CR19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","volume":"8","author":"CL Trotter","year":"2009","unstructured":"Trotter CL, Maiden MCJ. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines. 2009;8(7):851\u201361.","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"65_CR20","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","volume":"14","author":"D Stamboulian","year":"2010","unstructured":"Stamboulian D, Lopardo G, Lopez P, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM (197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. 2010;14(10):e868\u201375.","journal-title":"Int J Infect Dis"},{"key":"65_CR21","doi-asserted-by":"crossref","unstructured":"Dbaibo G, Macalalad N, Reyes MRA-DL, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother 2012;8(7):873\u201380.","DOI":"10.4161\/hv.20211"},{"key":"65_CR22","doi-asserted-by":"crossref","unstructured":"Reyes MRA-DL, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8 (7):881\u20137.","DOI":"10.4161\/hv.20212"},{"key":"65_CR23","unstructured":"Nimenrix. Meningococcal group A, C, W 135 and Y conjugate vaccine. European Medicines Agency. 2012. 2012 Jun 22 [online]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002226\/human_med_001548.jsp&mid=WC0b01ac058001d124 ."},{"issue":"1","key":"65_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","volume":"27","author":"L Ostergaard","year":"2009","unstructured":"Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325\u00a0years. Vaccine. 2009;27(1):161\u20138.","journal-title":"Vaccine"},{"issue":"3","key":"65_CR25","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","volume":"28","author":"M Knuf","year":"2010","unstructured":"Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28(3):744\u201353.","journal-title":"Vaccine"},{"issue":"3","key":"65_CR26","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","volume":"30","author":"R Baxter","year":"2011","unstructured":"Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25\u00a0years of age. Pediatr Infect Dis J. 2011;30(3):e41\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"25","key":"65_CR27","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","volume":"29","author":"T Vesikari","year":"2011","unstructured":"Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29(25):4274\u201384.","journal-title":"Vaccine"},{"issue":"4","key":"65_CR28","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","volume":"30","author":"ZA Memish","year":"2011","unstructured":"Memish ZA, Dbaibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J. 2011;30(4):e56\u201362.","journal-title":"Pediatr Infect Dis J"},{"issue":"25","key":"65_CR29","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","volume":"29","author":"M Knuf","year":"2011","unstructured":"Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with InfanrixTM hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children. Vaccine. 2011;29(25):4264\u201373.","journal-title":"Vaccine"},{"issue":"2","key":"65_CR30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","volume":"7","author":"N Bermal","year":"2011","unstructured":"Bermal N, Huang L-M, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccine. 2011;7(2):239\u201347.","journal-title":"Hum Vaccine"},{"issue":"2","key":"65_CR31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","volume":"4","author":"SE Maslanka","year":"1997","unstructured":"Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4(2):156\u201367.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"17\u201318","key":"65_CR32","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection\u2013serum bactericidal antibody activity. Vaccine. 2005;23(17\u201318):2222\u20137.","journal-title":"Vaccine"},{"issue":"5","key":"65_CR33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","volume":"10","author":"N Andrews","year":"2003","unstructured":"Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780\u20136.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"65_CR34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","volume":"11","author":"ME Melville-Smith","year":"1983","unstructured":"Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11(2):137\u201344.","journal-title":"J Biol Stand"},{"issue":"1","key":"65_CR35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CDLI.11.1.83-88.2004","volume":"11","author":"H Jokhdar","year":"2004","unstructured":"Jokhdar H, Borrow R, Sultan A, et al. Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A\/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Immunol. 2004;11(1):83\u20138.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"10","key":"65_CR36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","volume":"159","author":"H Keyserling","year":"2005","unstructured":"Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159(10):907\u201313.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"7","key":"65_CR37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1128\/CVI.00039-12","volume":"19","author":"Y Al-Mazrou","year":"2012","unstructured":"Al-Mazrou Y, Khalil M, Findlow H, et al. Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccine: phase III, controlled, randomized, modified blind-observer study. Clin Vaccine Immunol. 2012;19(7):999\u20131004.","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"65_CR38","doi-asserted-by":"crossref","first-page":"e608-6","DOI":"10.1016\/j.ijid.2012.04.006","volume":"16","author":"G Dbaibo","year":"2012","unstructured":"Dbaibo G, Van der Wielen M, Reda M, et al. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Int J Infect Dis. 2012;16(8):e608-6.","journal-title":"Int J Infect Dis."},{"key":"65_CR39","unstructured":"United Nations Population Division. World population prospects: the 2010 revisions population database. 2011 [online]. Available from: http:\/\/esa.un.org\/unpd\/wpp\/unpp\/panel_indicators.htm ."},{"issue":"34","key":"65_CR40","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","volume":"28","author":"R Dagan","year":"2010","unstructured":"Dagan R, Poolman J, Siegrist C-A. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513\u201323.","journal-title":"Vaccine"},{"issue":"5","key":"65_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2458-5-5","volume":"12","author":"O Karabay","year":"2005","unstructured":"Karabay O, Ozkardes F, Tamer A, Karaarslan K. Tetanus immunity in nursing home residents of Bolu, Turkey. BMC Public Health. 2005;12(5):5.","journal-title":"BMC Public Health"},{"issue":"1\u20132","key":"65_CR42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2002-111-211","volume":"11","author":"E-RM Redwan","year":"2002","unstructured":"Redwan E-RM, Al-Awady MK. Prevalence of tetanus immunity in the Egyptian population. Hum Antibodies. 2002;11(1\u20132):55\u20139.","journal-title":"Hum Antibodies"},{"issue":"15","key":"65_CR43","first-page":"571","volume":"103","author":"G Cilla","year":"1994","unstructured":"Cilla G, S\u00e1enz-Dom\u00ednguez JR, Montes M, Part C, P\u00e9rez-Trallero E. Immunity against tetanus in adults over the age of 49\u00a0years. Med Clin. 1994;103(15):571\u20133.","journal-title":"Med Clin"},{"issue":"11","key":"65_CR44","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1185\/03007X233034","volume":"23","author":"H Theeten","year":"2007","unstructured":"Theeten H, R\u00fcmke H, Hoppener FJP, et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin. 2007;23(11):2729\u201339.","journal-title":"Curr Med Res Opin"},{"issue":"35","key":"65_CR45","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1016\/j.vaccine.2011.06.049","volume":"29","author":"P Damme Van","year":"2011","unstructured":"Van Damme P, McIntyre P, Grimprel E, et al. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(\u00ae)) in adults 55\u00a0years of age and over: a sub-analysis of four trials. Vaccine. 2011;29(35):5932\u20139.","journal-title":"Vaccine"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0065-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0065-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:44:43Z","timestamp":1644565483000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0065-0","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}